Skip to main content
MANE
NYSE Life Sciences

Veradermics Prices Initial Public Offering at $17.00 Per Share, Raising $256M to Advance Hair Loss Therapeutic

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$37.15
Mkt Cap
--
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Veradermics, Inc. has priced its Initial Public Offering of 15,077,647 shares at $17.00 per share, generating approximately $256.3 million in gross proceeds to fund the development and commercialization of its lead hair loss therapeutic, VDPHL01.


Key Events · Financing and Capital Events · MANE

  • Initial Public Offering Priced

    Veradermics priced its IPO of 15,077,647 shares of common stock at $17.00 per share, raising approximately $256.3 million in gross proceeds.

  • Substantial Capital Infusion

    The company expects to receive approximately $234.0 million in net proceeds, which will be used to fund the development of its lead candidate VDPHL01 through NDA approval and initial commercialization.

  • Strategic Investor Participation

    Eli Lilly and Wellington Management indicated interest in purchasing a significant portion of the offering, signaling institutional confidence.

  • Lead Product Advancement

    Funds will support ongoing Phase 2/3 and Phase 3 clinical trials for VDPHL01, an oral, non-hormonal treatment for pattern hair loss, with topline data from a key male trial expected in H1 2026.


Analysis · MANE · Life Sciences

This Initial Public Offering (IPO) is a pivotal event for Veradermics, a clinical-stage biopharmaceutical company, as it establishes its public market presence and secures substantial capital. The $234.0 million in net proceeds will primarily fund the advancement of VDPHL01, an extended-release minoxidil for pattern hair loss, through its pivotal Phase 3 trials and into initial commercialization. The strong investor interest, including indications from Eli Lilly and Wellington Management, underscores confidence in the company's pipeline and commercial strategy, particularly its focus on a cash-pay market for a potentially first-in-class oral, non-hormonal FDA-approved therapy for female pattern hair loss. The significant difference between the IPO price of $17.00 and the current market price of $37.15 suggests robust post-IPO demand and positive market reception.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $37.15 on NYSE in the Life Sciences sector. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $128.30 info
Change: -$1.36 (-1%) info
Market Cap: $5.471B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $128.30 info
Change: -$20.14 (-14%) info
Market Cap: $5.471B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $128.30 info
Change: -$14.42 (-10%) info
Market Cap: $5.471B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $128.30 info
Change: -$13.70 (-10%) info
Market Cap: $5.471B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $128.30 info
Change: -$11.03 (-8%) info
Market Cap: $5.471B info